Technology
Health
Medical
Axonics Modulation
$30.249876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$30.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.09 (0.30%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell AXNX and other stocks, options, ETFs, and crypto commission-free!
About
Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Read More It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.
Employees
87
Headquarters
Irvine, California
Founded
2012
Market Cap
852.80M
Price-Earnings Ratio
â
Dividend Yield
â
Average Volume
158.88K
High Today
$30.43
Low Today
$29.35
Open Price
$29.99
Volume
62.84K
52 Week High
$32.90
52 Week Low
$11.95
Collections
Technology
Health
Medical
2018 IPO
US
North America
News
Yahoo FinanceMay 8
AxonicsÂŽ Announces First Quarter 2019 Financial Results and Operational Update
Yahoo FinanceApr 24
AxonicsÂŽ to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (âSNMâ) devices for the treatment of urinary and bowel dysfunction, today announced that it will release financial results for the first quarter of 2019 and provide an update on operations and FDA regulatory status after the market closes on Wednesday, May 8, 2019. In conjunction with the release, the Compa...
Price Paid on Robinhood
28% Higher
Right Now
52 Week Low
$11.95
Average Price Paid
$23.58
52 Week High
$32.90
Earnings
-$2.67
-$1.89
-$1.12
-$0.34
Q3 2018
Q4 2018
Q1 2019
Estimated
â
Actual
-$0.47 per share